The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus
Open accessAbstract
Background & aims Experimental evidence indicates that proton pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs)/aspirin, and statins can protect patients with Barrett's esophagus (BE) from developing neoplasias. However, only limited data are available on chemoprevention in patients with BE.Methods A retrospective observational study was performed using data from patients with documented BE. Prescription information was collected from pharmacy records. Cox regression analyses were performed to examine the association between prescriptions for PPIs, NSAIDs/aspirin, or statins and the risk of developing esophageal dysplasia or adenocarcinoma during follow-up (from 1982 to 2005).Results We examined 344 patients diagnosed with BE (mean age 61 years, 90.4% Caucasian, 94.2% male). After BE diagnosis, 67.2% of the patients were prescribed PPIs for a mean duration of 5.1 years; 49.1% were prescribed NSAIDs for a mean duration of 3.6 years, and 25.3% were prescribed statins for a mean duration of 2.8 years. During 2620 patient-years, high grade dysplasia or esophageal adenocarcinoma developed in 33 patients. PPI treatment after BE diagnosis was associated with a reduced risk of high grade dysplasia or cancer; this association persisted after adjustment for gender, age, and the length of BE. NSAID and/or aspirin therapy were associated with a nonsignificant trend toward lower incidence of high grade dysplasia or esophageal cancer.Conclusions PPI therapy reduces the risk of neoplasms in patients with BE. NSAIDs/aspirin appear to reduce cancer risk whereas statin use is not significantly associated with the risk of neoplasia in patients with BE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“because their long-term use significantly decreases the risk of the progression to high-grade dysplasia and EAC[50-52]”
From Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified (2019) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma
Lagergren, J., Bergström, R., Lindgren, A., & Nyrén, O. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903183401101 · Cited by 3,012
Wilkinson, E. (2002) · Nature Cell Biology · doi:10.1016/s1470-2045(02)00737-4 · Cited by 951
Corley, D. A., Kerlikowske, K. M., Verma, R., & Buffler, P. A. (2003) · Gastroenterology · doi:10.1053/gast.2003.50008 · Cited by 524
Chow, W.-H. (1995) · JAMA · doi:10.1001/jama.1995.03530060048032 · Cited by 376
Buttar, N. S., Wang, K. K., Leontovich, O. N., Westcott, J. Y., Pacifico, R. J., Anderson, M. A., Krishnadath, K. K., Lutzke, L. S., & Burgart, L. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.32371 · Cited by 346
Proton Pump Inhibitors Are Associated with Reduced Incidence of Dysplasia in Barrett's Esophagus
El‐Serag, H. B., Aguirre, T. V., Davis, S., Kuebeler, M. K., Bhattacharyya, A., & Sampliner, R. E. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30228.x · Cited by 329
Self-citation3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer
Blais, L., Desgagné, A., & LeLorier, J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.15.2363 · Cited by 326
Cyclooxygenase-2 Expression in The Barrettʼs Metaplasia–Dysplasia–Adenocarcinoma Sequence
Morris, C. D., Armstrong, G. R., Bigley, G., Green, H. E., & Attwood, S. E. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03599.x · Cited by 250
Vaughan, T. L., Dong, L. M., Blount, P. L., Ayub, K., Odze, R. D., Sanchez, C. A., Rabinovitch, P. S., & Reid, B. J. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70431-9 · Cited by 216
Proton‐pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus
Hillman, L. C., Chiragakis, L., Kaye, G., Clarke, A. C., & Shadbolt, B. (2004) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2004.tb05991.x · Cited by 194
Flagged first, then by citations
1 of the 20 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–159 of 159
Barrett's esophagus: prevalence and incidence of adenocarcinomas
Shields, H. M., Nardone, G., Zhao, J., Wang, W., Xing, Z., Fang, D.-C., Jacobson, B. C., Romero, Y., Dvorak, K., Goldman, A. J., et al. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06054.x · Cited by 7
Barrett Esophagus and Esophageal Adenocarcinoma
Spechler, S. J., & Souza, R. F. (2008) · Wiley eBooks · doi:10.1002/9781444303254.ch35 · Cited by 7
Ye, X., Yao, Z., Weidong, L., Xun, P., & Sidong, C. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3560 · Cited by 6
Watson, J. T., Moawad, F. J., Veerappan, G. R., Bassett, J. T., Maydonovitch, C. L., Horwhat, J. D., & Wong, R. K. H. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2763-1 · Cited by 6
“As persistent exposure to intra-esophageal acid is the premise behind the development of Barrett’s esophagus, one would surmise that adequate control of acid should decrease any further mucosal damage and potentially prevent the development of more advanced manifestations of disease such as stricture, ulceration, and…”
BackgroundSpechler, S. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3794-9_49 · Cited by 6
Epidemiology of esophageal carcinoma
Shakhatreh, M. H., & El‐Serag, H. B. (2015) · doi:10.1002/9781118655153.ch1 · Cited by 6
Self-citationAntireflux and Endoscopic Therapies for Barrett Esophagus and Superficial Esophageal Neoplasia
Fedorova, E., & Watson, T. J. (2021) · Surgical Clinics of North America · doi:10.1016/j.suc.2021.03.002 · Cited by 5
Radiofrequency ablation for low-grade dysplasia in Barrett's esophagus
Lodhia, N. A., Whitcomb, E., & Ja, K. V. (2016) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000277 · Cited by 5
Acid suppression and surgical therapy for Barrett's oesophagus
de Jonge, P. J. F., Spaander, M. C. W., Bruno, M. J., & Kuipers, E. J. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.11.005 · Cited by 5
Dutta, S., Agrawal, K., Girotra, M., Fleisher, A. S., Motevalli, M., Mahʼmoud, M. A., & Nair, P. P. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.12.6011 · Cited by 4
“…long-term treatment of GERD by anti-reflux therapies in patients with Barrett’s esophagus may lower the incidence of esophageal adenocarcinoma (Hillman, 2004; Cooper, 2006; Nguyen et al., 2009). β-carotene, a naturally occurring phytocarotenoid, is the primary dietary source of pro-vitamin A.”
BackgroundBarrett's esophagus: A comprehensive review for the internist
Klavan, H. L., Russell, M. B., Macklin, J., Lee, E. H. M., Aslanian, H. R., & Muniraj, T. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2018.04.001 · Cited by 4
Marano, S., Mattacchione, S., Luongo, B., Mingarelli, V., Campagna, G., & Tosato, F. (2013) · Surgical Laparoscopy Endoscopy & Percutaneous Techniques · doi:10.1097/sle.0b013e31828b8758 · Cited by 4
“0001 Vitality 60 (5-85)* 55 (5-88)* NS 65 (25-100)* NS 55 (15-90)* NS Social functioning 58 (SD±27.”
Barrett's esophagus: surgical treatments
Parise, P., Rosati, R., Savarino, E. V., Locatelli, A., Ceolin, M., Dua, K. S., Tatum, R. P., Braghetto, I., Gyawali, C. P., Hejazi, R. A., et al. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06051.x · Cited by 4
Cancer Prevention in Patients with GERD and Barrett’s Esophagus—Medicine
Scarpignato, C., & Wang, D. H. (2021) · Foregut The Journal of the American Foregut Society · doi:10.1177/2634516121993676 · Cited by 3
Quality in Barrett's Esophagus: Diagnosis and Management
Konda, V. J. A., Ellison, A. C., Codipilly, D. C., Han, J. Y., Samarasena, J., & Iyer, P. G. (2022) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2022.01.009 · Cited by 3
Barrett's esophagus: results from an Italian cohort with tight endoscopic surveillance.
Rodriguez-Castro, K. I., Crafa, P., Franceschi, M., Franzoni, L., Brozzi, L., Ferronato, A., Morini, A., Cuoco, L., Baldassarre, G., Pertoldi, B., et al. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93i1.11987 · Cited by 3
Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett’s Esophagus
Shah, S. L., & Dunbar, K. B. (2023) · Current Gastroenterology Reports · doi:10.1007/s11894-023-00905-5 · Cited by 3
“Some of the first studies of chemoprevention of neoplasia in BE were performed using pharmacy data from the Department of Veteran Affairs Hospital [26, 27].”
Surgical Treatment of Gastroesophageal Reflux Disease
Tosato, F., Marano, S., Mattacchione, S., Luongo, B., Paltrinieri, G., Mingarelli, V., & Vasapollo, L. (2011) · InTech eBooks · doi:10.5772/24145 · Cited by 3
Barrett's esophagus: proton pump inhibitors and chemoprevention I
Triadafilopoulos, G., Taddei, A., Bechi, P., Freschi, G., Ringressi, M. N., Degl’Innocenti, D. R., Castiglione, F., Masini, E., Majewski, M., Wallner, G. T., et al. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06047.x · Cited by 3
The Clinician’s Guide to Proton-Pump Inhibitor Discontinuation
Wiens, E. J., Kovaltchouk, U., Koomson, A., & Targownik, L. E. (2019) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001243 · Cited by 3
Chemoprevention in Barrett's Esophagus: Are We There Yet, Are We There Yet …?
Corley, D. A. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.09.003 · Cited by 3
Clinical issues in oesophageal adenocarcinoma: could DNA copy number hold the key?
Frankel, A. J., Nancarrow, D. J., Wayte, N., & Barbour, A. P. (2012) · ANZ Journal of Surgery · doi:10.1111/j.1445-2197.2012.06144.x · Cited by 2
“There has only been one study of intratumoural genetic heterogeneity in OAC.”
BackgroundInfluentialESÓFAGO DE BARRETT: REVISIÓN DE LA LITERATURA
R., M. A. R., & Fernando Fluxá, G. (2015) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2015.09.002 · Cited by 2
Barrett's oesophagus: how should we manage it?
Old, O. J., Almond, M., & Barr, H. (2015) · Frontline Gastroenterology · doi:10.1136/flgastro-2014-100552 · Cited by 2
Biomarkers in Exploring the Frontiers of Diagnosis, Prognosis, and Therapy of Barrett's Esophagus
Yachimski, P., & Peek, R. M. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0204 · Cited by 2
Chemoprevention in Barrett’s Esophagus: An Updated Review
Samnani, S. S., Jankowski, J. A., & Moayyedi, P. (2025) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2025.05.004 · Cited by 1
Diagnosis and Management of Barrett’s Esophagus with and Without Dysplasia
Vladimirov, B. G., Ivanova, R., & Terziev, I. (2013) · InTech eBooks · doi:10.5772/52735 · Cited by 1
“These data suggested that initiating PPI therapy soon after the diagnosis of BE may prevent this progression [148, 150].”
BackgroundDiagnosis and management of Barrett’s metaplasia: What’s new
Segal, F. (2012) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v4.i9.379 · Cited by 1
Chemoprevention of Barrett’s Esophagus and Adenocarcinoma
Şenateş, E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802511-6.00014-4 · Cited by 1
Medical and Surgical Therapy for Gastroesophageal Reflux Disease and Barrett Esophagus
Wendling, M. R., & Oelschlager, B. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-40232-3.00033-9 · Cited by 1
Barrett’s Esophagus: A Review of Current Literature
Eagleston, J., Yoder, L., & Kakar, K. (2023) · Springer eBooks · doi:10.1007/978-3-031-39199-6_29 · Cited by 1
Sollano, J. D., Romano, R. P., Ibañez-Guzman, L., Lontok, M. A., Ocampo, S. D., Policarpio, A. A., de Guzman, R. N., Dalupang, C. D., Galang, A. J. G., Olympia, E. G., et al. (2015) · Philippine Journal of Internal Medicine · doi:10.65564/pjim.9662862c41 · Cited by 1
A review of the incidence of adenocarcinoma detected during surveillance for Barrett's esophagus
Vollmer, R. T. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.09.016 · Cited by 1
Hvid‐Jensen, F., Drewes, A. M., & Funch-Jensen, P. M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12931 · Cited by 1
Falk, G. W. (2012) · doi:10.1002/9781444346220.ch27 · Cited by 1
Studies of the aetiology of oesophageal adenocarcinoma
Cooper, S. C. (2013) · University of Birmingham Institutional Research Archive (University of Birmingham)
Miehlke, S. (2010) · Springer eBooks · doi:10.1007/978-3-642-11635-3_1
Is 325 mg of Prevention Worth a Pound of Cure?
Inadomi, J. M. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.08.015
Carcinogenesis of Barrett’s esophagus: a review of the clinical literature
Watari, J., Oshima, T., Fukui, H., Tomita, T., & Miwa, H. (2013) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-013-0412-z
Prevention of Barrett's metaplasia in a human model of duodenogastro-oesophageal reflux
Cade, R., Fox, A. M., Fahy, E. T., & Hii, M. W. (2013) · Gastroenterology Insights · doi:10.4081/gi.2013.e4
“O'Riordan (7) 2004 48 100 100 50 (24) 20 (14) 58”
Falk, G. W., Buttar, N. S., Foster, N. R., Ziegler, K. L. A., DeMars, C. J., Romero, Y., Marcon, N. E., Schnell, T. G., Corley, D. A., Sharma, P., et al. (2012)
Nguyen, D., Richardson, P. A., & El‐Serag, H. B. (2010)
Self-citationChemoprevention for Esophageal Carcinoma
Old, O. J., Almond, M., Barr, H., & Jankowski, J. A. (2015) · Springer eBooks · doi:10.1007/978-3-319-20068-2_5
Esophageal adenocarcinoma: risk factors
Naveed, M., & Dunbar, K. B. (2015) · doi:10.1002/9781118655153.ch4
Blackstock, A. W., & Russo, S. M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00043-2
Blackstock, A. W., & Russo, S. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00045-9
Barrett Esophagus and Esophageal Adenocarcinoma
Spechler, S. J., Wang, D. H., & Souza, R. F. (2015) · Yamada's Textbook of Gastroenterology · doi:10.1002/9781118512074.ch52
Marzio, D. H., & Arastu, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816569-0.00007-3
Kastelein, F. (2014) · EUR Research Repository (Erasmus University Rotterdam)
Elias, P. S., & Spechler, S. J. (2021) · doi:10.1002/9781119599692.ch29
Katzka, D. A. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717953895.793459589
Nguyen, A. D., Spechler, S. J., & Dunbar, K. B. (2019) · doi:10.1002/9781119211419.ch2
Stein, P. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-48890-1_22
Rajendra, S., & Sharma, P. (2016) · doi:10.1002/9781119127437.ch15
Nguyen, V. B. (2022) · Y HOC TP HO CHI MINH · doi:10.32895/ump.mpr.7.1.1
Darvishi, M., Heidari-Soureshjani, S., & Bidares, M. (2023) · Current Drug Research Reviews · doi:10.2174/2589977515666230112165525
Yachimski, P., & Peek, R. M. (2023) · doi:10.1158/1940-6207.c.6544658.v1
Khaghani, A., Kasiri, K., Heidari-Soureshjani, S., Sherwin, C. M. T., & Mardani-Nafchi, H. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206292712240522043350
Sehgal, P., & Choudhary, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26712-3.00005-7
Metadata
- Authors
- Nguyen, D. M., El-Serag, H. B., Henderson, L., Stein, D., Bhattacharyya, A., & Sampliner, R. E.
- Affiliations
- Michael E. DeBakey VA Medical Center (US)
- University of Arizona (US)
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 7
- Issue
- 12
- Pages
- 1299-1304
- ISSN
- 1542-3565 (ISSN-L)
- PMC
- PMC2789910
- OpenAlex
- W2071302779
- Cited by
- 159
- References
- 20
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 13 · 2020: 4 · 2019: 8 · 2018: 4 · 2017: 9 · 2016: 4 · 2015: 15 · 2014: 15 · 2013: 17 · 2012: 25
- FWCI
- 18.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Gastroenterology and Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA116845)
- National Institute of Diabetes and Digestive and Kidney Diseases (K24DK078154, DK 563338)
- Topics
- Health Sciences › Medicine › Surgery › Esophageal Cancer Research and Treatment
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Health Sciences › Medicine › Surgery › Esophageal and GI Pathology
- Keywords
- Barrett's esophagus, proton pump inhibitors, nonsteroidal anti-inflammatory drugs, aspirin, statins, chemoprevention, esophageal adenocarcinoma, high-grade dysplasia, neoplasia risk, medication use
- MeSH terms
- Aged, Anti-Inflammatory Agents, Non-Steroidal, Barrett Esophagus, Esophageal Neoplasms, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Drug Monitoring, Proton Pump Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
